Dr. Ronald Brenner, MD

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 89 payments worth $31,902 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 17 industry-funded studies in 2025, from 7 companies. The companies reported $1,734,060 in research payments for these studies, mostly to the institutions running them.

• A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patie…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
  Hoffmann-la Roche Limited
• Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
  AbbVie Inc. · Completed · NCT06605599
• A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia
  Boehringer Ingelheim International GmbH
• An open label, single arm, extension trial to examine long-termsafety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X)
  Boehringer Ingelheim Pharmaceuticals, Inc.
• Connex-2
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1…
  Boehringer Ingelheim International GmbH
• A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
  Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
• An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
  Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
• Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM
  Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Psychiatry clinicians in Rockville Centre

• Shiby Abraham, MD
• Barbara Ambrosino, M.D.
• Georges J. Casimir, M.D
• Nadia Habib, MD
• Lubomir M. Kanov, MD
• Ashitbharat Kothari, MD
• Omanamhe Masagbor, M.D
• Yahya Moadel, MD